Key Highlights

● Delcath soared on November 9 after third-quarter results.

● Revenue of $35.1 million compared with $20.6 million a year earlier.

● The 2026 Revenue forecast rose to $115 million to $117 million.

● Growth was driven by the HEPZATO KIT.

A quarter that changed the conversation

Delcath Systems (NASDAQ:DCTH) was one of the standout winners among small caps on Monday, November 9, 2026, after the medical technology company reported third-quarter numbers that dwarfed its year-ago performance. Revenue came in at $35.1 million, up from $20.6 million in the same quarter of 2025, driven by its HEPZATO KIT, a liver-directed therapy used to treat melanoma that has spread to the liver.

Management also lifted its 2026 revenue forecast to a range of $115 million to $117 million. For a company whose story rests largely on a single commercial product, a sharp sales increase paired with a higher forecast tends to grab investor attention quickly, and Monday was no exception.

The stock soared. Live market data showed the shares sharply higher in the early afternoon, while another reading captured an even larger gain later in the session.

What Delcath actually sells

HEPZATO KIT is designed to deliver a high dose of chemotherapy directly to the liver while limiting exposure to the rest of the body. The approach is aimed at patients whose melanoma has spread to the liver, a group with limited treatment options. Because the procedure is performed at specialized treatment centers, revenue growth depends on how many hospitals adopt the system and how often they use it.

That is why investors read the jump in quarterly revenue as a signal about adoption. A higher full-year range suggests the company expects that momentum to continue through the final months of the year.

A tide that lifted small caps

Delcath's surge came on one of the strongest days of the year for smaller companies. The Russell 2000 climbed 86.71 points to close at 2,840.81, its best session since March 31, outpacing the large-cap benchmarks. The S&P 500 added 173.08 points to 7,549.94, while the Dow Jones Industrial Average gained 1,104.02 points to 52,389.75.

The rally had several engines. Oil slid sharply on hopes of progress in US-Iran talks, with Brent Crude settling at $92.57 after starting the month above $112, according to news reports. That eased Inflation worries ahead of Tuesday's consumer price report. Chip stocks also rebounded hard after a punishing prior week, and all 11 S&P 500 sectors finished higher.

Health care names had a busy day of their own. Vir Biotechnology (NASDAQ:VIR) and Immunovant (NASDAQ:IMVT) both jumped on positive trial data, showing that investors were willing to reward clear, company-specific good news.

Why guidance matters for a company this size

For small medical technology firms, a raised outlook often carries more weight than a single quarter's beat. It tells investors that management sees enough visibility in orders and treatment volumes to commit to a higher number publicly.

Hospital Adoption Drives Growth

The next test for Delcath is whether it can deliver on its raised 2026 forecast of $115 million to $117 million when it reports fourth-quarter results. Investors will be watching for evidence that new treatment centers keep coming online and that existing sites are using HEPZATO KIT more often.

The broader backdrop matters too. Tuesday's October Consumer Price Index is the last inflation reading before the Federal Reserve's December 8-9 meeting, where traders see a rate hike as likely. Small-cap stocks tend to be sensitive to borrowing costs, so a hot inflation print could test Monday's enthusiasm across the Russell 2000.